» Articles » PMID: 28367476

Obesity, Diabetes and Cancer: A Mechanistic Perspective

Overview
Date 2017 Apr 4
PMID 28367476
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Nearly 35% of adults and 20% of children in the United States are obese, defined as having a body mass index (BMI) ≥ 30 kg/m. Obesity is an established risk factor for many cancers, and obesity-associated metabolic perturbations often manifest in Type 2 diabetes mellitus and/or the metabolic syndrome. As part of the growth-promoting, proinflammatory microenvironment of the obese and/or diabetic state, crosstalk between macrophages, adipocytes, and epithelial cells occurs via metabolically-regulated hormones, cytokines, and other mediators to enhance cancer risk and/or progression. This review synthesizes the evidence on key biological mechanisms underlying the associations between obesity, diabetes and cancer, with particular emphasis on enhancements in growth factor signaling, inflammation, and vascular integrity processes. These interrelated pathways represent mechanistic targets for disrupting the obesity-diabetes-cancer link, and several diabetes drugs, such as metformin and rosiglitazone, are being intensely studied for repurposing as cancer chemopreventive agents.

Citing Articles

Linking the metabolic syndrome and obesity with vitamin D status: risks and opportunities for improving cardiometabolic health and well-being.

Moukayed M, Grant W Diabetes Metab Syndr Obes. 2019; 12:1437-1447.

PMID: 31496777 PMC: 6701609. DOI: 10.2147/DMSO.S176933.


The Beneficial Effects of Quercetin, Curcumin, and Resveratrol in Obesity.

Zhao Y, Chen B, Shen J, Wan L, Zhu Y, Yi T Oxid Med Cell Longev. 2017; 2017:1459497.

PMID: 29138673 PMC: 5613708. DOI: 10.1155/2017/1459497.

References
1.
Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

2.
Barb D, Williams C, Neuwirth A, Mantzoros C . Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2008; 86(3):s858-66. DOI: 10.1093/ajcn/86.3.858S. View

3.
Larsson S, Orsini N, Wolk A . Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(22):1679-87. DOI: 10.1093/jnci/dji375. View

4.
Everhart J, Wright D . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273(20):1605-9. View

5.
Wu M, Chou Y, Chou W, Hsu G, Chu C, Yu C . Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100(4):578-82. PMC: 2653731. DOI: 10.1038/sj.bjc.6604913. View